Carl M. Vahldieck
Luebeck, SH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study.
Journal: Journal of critical care
Published: June 04, 2026
Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk.
Journal: Frontiers in immunology
Published: February 17, 2026
Activation of the C3a-C3aReceptor-axis is associated with endothelial dysfunction and glycocalyx damage in ST-elevation myocardial infarction.
Journal: Basic research in cardiology
Published: December 12, 2025
Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study.
Journal: BMC cardiovascular disorders
Published: December 11, 2025
Amlodipine improves aortic dysfunction in atherosclerotic mice.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 08, 2025
The anti-atherosclerotic effect of chronic AT1 receptor blocker treatment also depends on the ACE2/Ang(1-7)/Mas axis.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 16, 2025
Dysregulated autoantibodies targeting AGTR1 are associated with the accumulation of COVID-19 symptoms.
Journal: NPJ systems biology and applications
Published: May 09, 2024
Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis.
Journal: Frontiers in immunology
Published: May 01, 2024
Prolonged Door-to-Balloon Time Leads to Endothelial Glycocalyx Damage and Endothelial Dysfunction in Patients with ST-Elevation Myocardial Infarction.
Journal: Biomedicines
Published: September 18, 2023
Endothelial Glycocalyx and Cardiomyocyte Damage Is Prevented by Recombinant Syndecan-1 in Acute Myocardial Infarction.
Journal: The American journal of pathology
Published: May 31, 2022
Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage.
Journal: Pflugers Archiv : European journal of physiology
Published: May 10, 2022
Short regulatory DNA sequences to target brain endothelial cells for gene therapy.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
Published: August 24, 2021
Last Updated: 09/26/2026